WHO opened its first substance-use-disorder medicine prequalification invitation on May 22, 2026. The June 3 announcement named methadone, sublingual buprenorphine, and naloxone. WHO estimates 316 million people use psychoactive drugs annually. About 61 million people use opioids non-medically worldwide. More quality-assured suppliers could strengthen treatment and overdose-prevention access.
Why Did WHO Open Addiction Medicine Prequalification?
Treatment access remains uneven because many countries lack reliable supplies of quality-assured medicines. In 2026, WHO opened its Prequalification Programme to methadone, sublingual buprenorphine, and naloxone submissions. Generic manufacturers may now present eligible dossiers for assessment. However, an invitation is not approval, national registration, guaranteed procurement, or unrestricted controlled-medicine distribution. Each product must satisfy quality, safety, efficacy, and inspection requirements.
Prequalification Could Reshape Global Treatment Access
WHO prequalification may create new opportunities, but manufacturers face dossier costs, GMP remediation, bioequivalence requirements, and controlled-medicine restrictions. Methadone, buprenorphine, and naloxone also remain subject to national registration, import, and distribution controls. Successful assessment could expand quality-assured supply, strengthen UN procurement confidence, improve treatment continuity, and support overdose prevention. Generic manufacturers, public-health programmes, regulators, and procurement agencies must still manage affordability, infrastructure, demand forecasting, and legal access barriers across markets.
GMP, Dossiers, and Procurement Skills Matter
GMP, dossier, and procurement expertise now connect manufacturing quality with global access. Regulatory professionals, quality specialists, API manufacturers, bioequivalence teams, graduates, and international applicants must understand WHO eligibility, technical assessment, inspection readiness, controlled-medicine obligations, and public-health supply decisions across markets.
Why Manufacturers Need Submission-Ready Dossiers
Manufacturers need submission-ready dossiers covering eligibility, quality, safety, efficacy, bioequivalence, stability, API controls, manufacturing processes, and product information. Weak or incomplete evidence may prevent screening or delay assessment substantially today.
- Confirm product eligibility before preparing the complete prequalification dossier.
- Review quality, bioequivalence, stability, API, and product-information evidence before submission.
How GMP Teams Should Prepare Sites
GMP teams should prepare quality systems, data integrity, process validation, cleaning validation, supplier controls, deviations, CAPA, change control, laboratories, and inspection evidence before WHO evaluates manufacturing sites for compliance globally.
- Conduct a detailed gap assessment against applicable WHO GMP requirements.
- Verify CAPA, validation, data-integrity, supplier, and laboratory controls before inspection.
Why Global Access Careers Are Expanding
Global access careers increasingly combine WHO prequalification, procurement, regulatory strategy, GMP, supply chains, tender preparation, and controlled-medicine compliance. Candidates should demonstrate how quality-assured products reach regulated public-health programmes internationally today.
- Add WHO prequalification, procurement, GMP, and dossier experience to your resume.
- Prepare an interview example involving quality-assured supply for controlled medicines.
What Could WHO Prequalification Achieve?
Following the May 22, 2026 invitation, successful prequalification could expand eligible manufacturers, strengthen quality-assured supply, and improve procurement confidence. Wider naloxone availability may support overdose response, while methadone and buprenorphine access may improve treatment continuity. The initiative could also create demand for regulatory, GMP, dossier, procurement, and access specialists globally.
Prepare for WHO prequalification with Pharmuni. Read Global Pharma Regulatory Bodies: 2026 Guide, follow the GMP Basics Career Path.